Urinary Tract Cancer Market by Cancer type (Bladder Cancer, Urethral cancer and Ureteric and Renal Pelvic Cancer), Treatment Type (Chemotherapy, and Immunotherapy), and Distribution Channel (Retail Pharmacy, and Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2021––2030
- ALL4676928
- 249 Pages
- September 2021
- Diagnostic and Biotech
Urinary tract cancer is defined as the type of cancer, which develop a lesion ranging from small benign tumors to aggressive neoplasm with high mortality. The urinary tract cancer is found in the bladder, ureters, renal pelvis, and urethra. The most common urinary tract cancer is bladder cancer. The sign and symptoms of urinary tract cancer are blood clots in the urine, frequent urination, and back pain.
The global urinary tract cancer market is majorly driven by an alarming increase in the prevalence of bladder cancer, a rise in government initiative for prevention and treatment of bladder cancer, availability of advanced therapy, increase in number of approval of drugs, and rise in funds for R&D activities. For instance, according to the American Cancer Society, in 2021, approximately 17,200 deaths were reported due to bladder cancer, in the U.S., and around 83,730 population are diagnosed with this disease. Bladder cancer is the tenth most common cancer, across the globe. Moreover, in January 2021, the European Commission announced the approval of Bavencio (avelumab), which is used for the treatment of locally advanced or metastatic urothelial carcinoma. Furthermore, in 2020, Bristol Myers Squibb, a global pharmaceutical company, spends $11.1 billion in R&D activities. In addition, rise in the geriatric population, who are more vulnerable to urinary tract cancer, drive the growth of the market. Further, increase in need for available biologic therapy and rise in prevalence of urinary tract cancer are expected to propel the growth of the market.
Increase in number of R&D activities and advancement in healthcare services are the major factors that drive the global urinary tract cancer market. Moreover, increase in sedentary lifestyle significantly contributes toward the market growth, owing to the fact that smoker, and alcohol consumers are more susceptible to bladder cancer. According to the National Institute of Health (NIH), in 2018, it was observed that around 50% of all the case of bladder cancer are diagnosed in smokers. Rise in demand for early diagnosis of disease for effective treatment acts a key driving force of the global market. Furthermore, governments are taking multiple initiatives to support healthcare infrastructure and increase the healthcare spending, which is expected to boost the market growth. According to Centers for Medicare & Medicaid Services (CMC), in 2019, it was reported that the U.S. health care spending increased by 4.6% to reach $3.8 trillion, or $11,582 per person. It allows the healthcare organization to develop and produce advanced therapy for the treatment of urinary tract cancer. In addition, increase in number of bladder cancer research centers is anticipated to provide lucrative opportunities for the market expansion. For instance, in November 2020, the University of Birmingham, in the UK, announced the launch of bladder cancer research centers, which aims to translate biomedical science into healthcare benefits for patients suffering from bladder cancer. A combination of University investment and philanthropic donation funded $1.23 million for the development of bladder cancer research centers.
On the contrary, risk associated with the use of drugs for treatment of bladder cancer such as irritation in bladder, blood in urine, and infection is anticipated to hinder the market growth during the forecast period. The rise in health reimbursement and presence of highly specialized urologist for cancer treatment leads to the enhancement of the urinary tract cancer sector. This encourages many key players to enter emerging markets, thus offering a lucrative growth opportunity in the urinary tract cancer market.
The global urinary tract cancer market is segmented into cancer type, treatment type, distribution channel, and region. By cancer type, the market is categorized into bladder cancer, urethral cancer, and ureteric and renal pelvic cancer.
By treatment type, it is divided into chemotherapy, and immunotherapy. By distribution channel, the market is bifurcated into retail pharmacy, and online pharmacy. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global urinary tract cancer market are Astellas Pharma Inc., Bristol-Myers Squibb Company, Eli Lily and Company, Endo International plc., Exelixis, Inc., GlaxoSmithKline Plc.(GSK), Merck KGAA, Novartis AG, Pfizer Inc., and Johnson & Johnson.
KEY BENEFITS FOR STAKEHOLDERS
The report provides an in-depth analysis of the global urinary tract cancer market size along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global urinary tract cancer market.
KEY MARKET SEGMENTS
By Cancer type
• Bladder Cancer
• Urethral cancer
• Ureteric and Renal Pelvic Cancer
By Treatment Type
• Chemotherapy
o Retail Pharmacy
o Online Pharmacy
• Immunotherapy
o Retail Pharmacy
o Online Pharmacy
By Distribution Channel
• Retail Pharmacy
• Online Pharmacy
By Region
o North America
U.S.
Canada
Mexico
o Europe
Germany
France
UK
Italy
Spain
Rest of Europe
o Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
o LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
KEY MARKET PLAYERS
• Astellas Pharma Inc.
• Bristol-Myers Squibb Company
• Eli Lily and Company
• Endo International plc.
• Exelixis, Inc.
• GlaxoSmithKline Plc. (GSK)
• Merck KGAA
• Novartis AG
• Pfizer Inc.
• Johnson & Johnson
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five forces analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in prevalence of urinary tract cancer
3.5.1.2.Increase in geriatric population
3.5.1.3.Increasing number of bladder cancer research centers
3.5.2.Restraint
3.5.2.1.Risk associated with the use of drugs employed in urinary tract cancer
3.5.3.Opportunity
3.5.3.1.Increase in healthcare expenditure worldwide
3.5.4.Impact analysis
3.6.Impact analysis of COVID-19 on the urinary tract cancer market
CHAPTER 4:URINARY TRACT CANCER MARKET, BY CANCER TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Bladder Cancer
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Urethral cancer
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.5.Ureteric and renal pelvic cancer
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
CHAPTER 5:URINARY TRACT CANCER MARKET, BY TREATMENT TYPE
5.1.Overview
5.1.1.Market size and forecast
5.2.Chemotherapy
5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by region
5.2.2.1.Chemotherapy by distribution channel
5.2.3.Market analysis, by country
5.3.Immunotherapy
5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast, by region
5.3.2.1.Immunotherapy by distribution channel
5.3.3.Market analysis, by country
CHAPTER 6:URINARY TRACT CANCER MARKET, BY DISTRIBUTION CHANNEL
6.1.Overview
6.1.1.Market size and forecast
6.2.Retail Pharmacy
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by region
6.2.3.Market analysis, by country
6.3.Online Pharmacy
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by region
6.3.3.Market analysis, by country
CHAPTER 7:URINARY TRACT CANCER MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America urinary tract cancer market, by cancer type
7.2.3.North America urinary tract cancer market, by treatment type
7.2.4.North America urinary tract cancer market, by distribution channel
7.2.5.Market size and forecast, by country
7.2.5.1.U.S.
7.2.5.1.1.U.S. urinary tract cancer market, by cancer type
7.2.5.1.2.U.S. urinary tract cancer market, by treatment type
7.2.5.1.3.U.S. urinary tract cancer market, by distribution channel
7.2.5.2.Canada
7.2.5.2.1.Canada urinary tract cancer market, by cancer type
7.2.5.2.2.Canada urinary tract cancer market, by treatment type
7.2.5.2.3.Canada urinary tract cancer market, by distribution channel
7.2.5.3.Mexico
7.2.5.3.1.Mexico urinary tract cancer market, by cancer type
7.2.5.3.2.Mexico urinary tract cancer market, by treatment type
7.2.5.3.3.Mexico urinary tract cancer market, by distribution channel
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe urinary tract cancer market, by cancer type
7.3.3.Europe urinary tract cancer market, by treatment type
7.3.4.Europe urinary tract cancer market, by distribution channel
7.3.5.Market size and forecast, by country
7.3.5.1.Germany
7.3.5.1.1.Germany urinary tract cancer market, by cancer type
7.3.5.1.2.Germany urinary tract cancer market, by treatment type
7.3.5.1.3.Germany urinary tract cancer market, by distribution channel
7.3.5.2.France
7.3.5.2.1.France urinary tract cancer market, by cancer type
7.3.5.2.2.France urinary tract cancer market, by treatment type
7.3.5.2.3.France urinary tract cancer market, by distribution channel
7.3.5.3.UK
7.3.5.3.1.UK urinary tract cancer market, by cancer type
7.3.5.3.2.UK urinary tract cancer market, by treatment type
7.3.5.3.3.UK urinary tract cancer market, by distribution channel
7.3.5.4.Italy
7.3.5.4.1.Italy urinary tract cancer market, by cancer type
7.3.5.4.2.Italy urinary tract cancer market, by treatment type
7.3.5.4.3.Italy urinary tract cancer market, by distribution channel
7.3.5.5.Spain
7.3.5.5.1.Spain urinary tract cancer market, by cancer type
7.3.5.5.2.Spain urinary tract cancer market, by treatment type
7.3.5.5.3.Spain urinary tract cancer market, by distribution channel
7.3.5.6.Rest of Europe
7.3.5.6.1.Rest of Europe urinary tract cancer market, by cancer type
7.3.5.6.2.Rest of Europe urinary tract cancer market, by treatment type
7.3.5.6.3.Rest of Europe urinary tract cancer market, by distribution channel
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific urinary tract cancer market, by cancer type
7.4.3.Asia-Pacific urinary tract cancer market, by treatment type
7.4.4.Asia-Pacific urinary tract cancer market, by distribution channel
7.4.5.Market size and forecast, by country
7.4.5.1.Japan
7.4.5.1.1.Japan urinary tract cancer market, by cancer type
7.4.5.1.2.Japan urinary tract cancer market, by treatment type
7.4.5.1.3.Japan urinary tract cancer market, by distribution channel
7.4.5.2.China
7.4.5.2.1.China urinary tract cancer market, by cancer type
7.4.5.2.2.China urinary tract cancer market, by treatment type
7.4.5.2.3.China urinary tract cancer market, by distribution channel
7.4.5.3.Australia
7.4.5.3.1.Australia urinary tract cancer market, by cancer type
7.4.5.3.2.Australia urinary tract cancer market, by treatment type
7.4.5.3.3.Australia urinary tract cancer market, by distribution channel
7.4.5.4.India
7.4.5.4.1.India urinary tract cancer market, by cancer type
7.4.5.4.2.India urinary tract cancer market, by treatment type
7.4.5.4.3.India urinary tract cancer market, by distribution channel
7.4.5.5.South Korea
7.4.5.5.1.South Korea urinary tract cancer market, by cancer type
7.4.5.5.2.South Korea urinary tract cancer market, by treatment type
7.4.5.5.3.South Korea urinary tract cancer market, by distribution channel
7.4.5.6.Rest of Asia-Pacific
7.4.5.6.1.Rest of Asia-Pacific urinary tract cancer market, by cancer type
7.4.5.6.2.Rest of Asia-Pacific urinary tract cancer market, by treatment type
7.4.5.6.3.Rest of Asia-Pacific urinary tract cancer market, by distribution channel
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA urinary tract cancer market, by cancer type
7.5.3.LAMEA urinary tract cancer market, by treatment type
7.5.4.LAMEA urinary tract cancer market, by distribution channel
7.5.5.Market size and forecast, by country
7.5.5.1.Brazil
7.5.5.1.1.Brazil urinary tract cancer market, by cancer type
7.5.5.1.2.Brazil urinary tract cancer market, by treatment type
7.5.5.1.3.Brazil urinary tract cancer market, by distribution channel
7.5.5.2.Saudi Arabia
7.5.5.2.1.Saudi Arabia urinary tract cancer market, by cancer type
7.5.5.2.2.Saudi Arabia urinary tract cancer market, by treatment type
7.5.5.2.3.Saudi Arabia urinary tract cancer market, by distribution channel
7.5.5.3.South Africa
7.5.5.3.1.South Africa urinary tract cancer market, by cancer type
7.5.5.3.2.South Africa urinary tract cancer market, by treatment type
7.5.5.3.3.South Africa urinary tract cancer market, by distribution channel
7.5.5.4.Rest of LAMEA
7.5.5.4.1.Rest of LAMEA urinary tract cancer market, by cancer type
7.5.5.4.2.Rest of LAMEA urinary tract cancer market, by treatment type
7.5.5.4.3.Rest of LAMEA urinary tract cancer market, by distribution channel
CHAPTER 8:COMPANY PROFILES
8.1.Astellas Pharma Inc.
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments
8.2.BRISTOL-MYERS SQUIBB COMPANY
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments
8.3.ELI LILY AND COMPANY
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.4.Endo International plc. (Endo Pharmaceutical)
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product Portfolio
8.4.5.Business performance
8.5.Exelixis, Inc.
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.6.GlaxoSmithKline Plc. (GSK)
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance.
8.7.MERCK KGAA
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.NOVARTIS AG
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.9.PFIZER INC.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product Portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments
8.10.JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC)
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments
TABLE 01.URINARY TRACT CANCER MARKET, BY CANCER TYPE, 2020–2030 ($MILLION)
TABLE 02.URINARY TRACT CANCER MARKET FOR BLADDER CANCER, BY REGION, 2020–2030 ($MILLION)
TABLE 03.URINARY TRACT CANCER MARKET FOR URETHRAL CANCER, BY REGION, 2020–2030 ($MILLION)
TABLE 04.URINARY TRACT CANCER MARKET FOR URETERIC AND RENAL PELVIC CANCER, BY REGION, 2020–2030 ($MILLION)
TABLE 05.GLOBAL URINARY TRACT CANCER MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 06.URINARY TRACT CANCER MARKET FOR CHEMOTHERAPY, BY REGION, 2020–2030 ($MILLION)
TABLE 07.CHEMOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 08.URINARY TRACT CANCER MARKET FOR IMMUNOTHERAPY, BY REGION, 2020–2030 ($MILLION)
TABLE 09.IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 10.GLOBAL URINARY TRACT CANCER MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 11.URINARY TRACT CANCER MARKET FOR RETAIL PHARMACY, BY REGION, 2020–2030 ($MILLION)
TABLE 12.URINARY TRACT CANCER MARKET FOR ONLINE PHARMACY, BY REGION, 2020–2030 ($MILLION)
TABLE 13.URINARY TRACT CANCER MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 14.NORTH AMERICA URINARY TRACT CANCER MARKET, BY CANCER TYPE, 2020-2030 ($MILLION)
TABLE 15.NORTH AMERICA URINARY TRACT CANCER MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 16.NORTH AMERICA URINARY TRACT CANCER MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 17.NORTH AMERICA URINARY TRACT CANCER MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 18.U.S. URINARY TRACT CANCER MARKET, BY CANCER TYPE, 2020-2030 ($MILLION)
TABLE 19.U.S. URINARY TRACT CANCER MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 20.U.S. URINARY TRACT CANCER MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 21.CANADA URINARY TRACT CANCER MARKET, BY CANCER TYPE, 2020-2030 ($MILLION)
TABLE 22.CANADA URINARY TRACT CANCER MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 23.CANADA URINARY TRACT CANCER MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 24.MEXICO URINARY TRACT CANCER MARKET, BY CANCER TYPE, 2020-2030 ($MILLION)
TABLE 25.MEXICO URINARY TRACT CANCER MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 26.MEXICO URINARY TRACT CANCER MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 27.EUROPE URINARY TRACT CANCER MARKET, BY CANCER TYPE, 2020-2030 ($MILLION)
TABLE 28.EUROPE URINARY TRACT CANCER MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 29.EUROPE URINARY TRACT CANCER MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 30.EUROPE URINARY TRACT CANCER MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 31.GERMANY URINARY TRACT CANCER MARKET, BY CANCER TYPE, 2020-2030 ($MILLION)
TABLE 32.GERMANY URINARY TRACT CANCER MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 33.GERMANY URINARY TRACT CANCER MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 34.FRANCE URINARY TRACT CANCER MARKET, BY CANCER TYPE, 2020-2030 ($MILLION)
TABLE 35.FRANCE URINARY TRACT CANCER MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 36.FRANCE URINARY TRACT CANCER MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 37.UK URINARY TRACT CANCER MARKET, BY CANCER TYPE, 2020-2030 ($MILLION)
TABLE 38.UK URINARY TRACT CANCER MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 39.UK URINARY TRACT CANCER MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 40.ITALY URINARY TRACT CANCER MARKET, BY CANCER TYPE, 2020-2030 ($MILLION)
TABLE 41.ITALY URINARY TRACT CANCER MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 42.ITALY URINARY TRACT CANCER MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 43.SPAIN URINARY TRACT CANCER MARKET, BY CANCER TYPE, 2020-2030 ($MILLION)
TABLE 44.SPAIN URINARY TRACT CANCER MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 45.SPAIN URINARY TRACT CANCER MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 46.REST OF EUROPE URINARY TRACT CANCER MARKET, BY CANCER TYPE, 2020-2030 ($MILLION)
TABLE 47.REST OF EUROPE URINARY TRACT CANCER MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 48.REST OF EUROPE URINARY TRACT CANCER MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 49.ASIA-PACIFIC URINARY TRACT CANCER MARKET, BY CANCER TYPE, 2020-2030 ($MILLION)
TABLE 50.ASIA-PACIFIC URINARY TRACT CANCER MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 51.ASIA-PACIFIC URINARY TRACT CANCER MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 52.ASIA-PACIFIC URINARY TRACT CANCER MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 53.JAPAN URINARY TRACT CANCER MARKET, BY CANCER TYPE, 2020-2030 ($MILLION)
TABLE 54.JAPAN URINARY TRACT CANCER MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 55.JAPAN URINARY TRACT CANCER MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 56.CHINA URINARY TRACT CANCER MARKET, BY CANCER TYPE, 2020-2030 ($MILLION)
TABLE 57.CHINA URINARY TRACT CANCER MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 58.CHINA URINARY TRACT CANCER MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 59.AUSTRALIA URINARY TRACT CANCER MARKET, BY CANCER TYPE, 2020-2030 ($MILLION)
TABLE 60.AUSTRALIA URINARY TRACT CANCER MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 61.AUSTRALIA URINARY TRACT CANCER MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 62.INDIA URINARY TRACT CANCER MARKET, BY CANCER TYPE, 2020-2030 ($MILLION)
TABLE 63.INDIA URINARY TRACT CANCER MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 64.INDIA URINARY TRACT CANCER MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 65.SOUTH KOREA URINARY TRACT CANCER MARKET, BY CANCER TYPE, 2020-2030 ($MILLION)
TABLE 66.SOUTH KOREA URINARY TRACT CANCER MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 67.SOUTH KOREA URINARY TRACT CANCER MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 68.REST OF ASIA-PACIFIC URINARY TRACT CANCER MARKET, BY CANCER TYPE, 2020-2030 ($MILLION)
TABLE 69.REST OF ASIA-PACIFIC URINARY TRACT CANCER MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 70.REST OF ASIA-PACIFIC URINARY TRACT CANCER MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 71.LAMEA URINARY TRACT CANCER MARKET, BY CANCER TYPE, 2020-2030 ($MILLION)
TABLE 72.LAMEA URINARY TRACT CANCER MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 73.LAMEA URINARY TRACT CANCER MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 74.LAMEA URINARY TRACT CANCER MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 75.BRAZIL URINARY TRACT CANCER MARKET, BY CANCER TYPE, 2020-2030 ($MILLION)
TABLE 76.BRAZIL URINARY TRACT CANCER MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 77.BRAZIL URINARY TRACT CANCER MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 78.SAUDI ARABIA URINARY TRACT CANCER MARKET, BY CANCER TYPE, 2020-2030 ($MILLION)
TABLE 79.SAUDI ARABIA URINARY TRACT CANCER MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 80.SAUDI ARABIA URINARY TRACT CANCER MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 81.SOUTH AFRICA URINARY TRACT CANCER MARKET, BY CANCER TYPE, 2020-2030 ($MILLION)
TABLE 82.SOUTH AFRICA URINARY TRACT CANCER MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 83.SOUTH AFRICA URINARY TRACT CANCER MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 84.REST OF LAMEA URINARY TRACT CANCER MARKET, BY CANCER TYPE, 2020-2030 ($MILLION)
TABLE 85.REST OF LAMEA URINARY TRACT CANCER MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 86.REST OF LAMEA URINARY TRACT CANCER MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 87.ASTELLAS: COMPANY SNAPSHOT
TABLE 88.ASTELLAS: OPERATING SEGMENT
TABLE 89.ASTELLAS: PRODUCT PORTFOLIO
TABLE 90.ASTELLAS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 91.BMS: COMPANY SNAPSHOT
TABLE 92.BMS: OPERATING SEGMENTS
TABLE 93.BMS: PRODUCT PORTFOLIO
TABLE 94.BMS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 95.ELI LILLY: COMPANY SNAPSHOT
TABLE 96.ELI LILLY: OPERATING SEGMENTS
TABLE 97.ELI LILLY: PRODUCT PORTFOLIO
TABLE 98.ENDO: COMPANY SNAPSHOT
TABLE 99.ENDO: OPERATING SEGMENTS
TABLE 100.ENDO: PRODUCT PORTFOLIO
TABLE 101.EXELIXIS: COMPANY SNAPSHOT
TABLE 102.EXELIXIS: OPERATING SEGMENT
TABLE 103.EXELIXIS: PRODUCT PORTFOLIO
TABLE 104.GSK: COMPANY SNAPSHOT
TABLE 105.GSK: OPERATING SEGMENTS
TABLE 106.GSK: PRODUCT PORTFOLIO
TABLE 107.MERCK: COMPANY SNAPSHOT
TABLE 108.MERCK: OPERATING SEGMENTS
TABLE 109.MERCK: PRODUCT PORTFOLIO
TABLE 110.MERCK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 111.NOVARTIS: COMPANY SNAPSHOT
TABLE 112.NOVARTIS: OPERATING SEGMENT
TABLE 113.NOVARTIS : PRODUCT PORTFOLIO
TABLE 114.PFIZER: COMPANY SNAPSHOT
TABLE 115.PFIZER: OPERATING SEGMENTS
TABLE 116.PFIZER: PRODUCT PORTFOLIO
TABLE 117.PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 118.J&J: COMPANY SNAPSHOT
TABLE 119.J&J: OPERATING SEGMENTS
TABLE 120.J&J: PRODUCT PORTFOLIO
TABLE 121.J&J : KEY STRATEGIC MOVES AND DEVELOPMENTS
Similar Reports
Complete report $6,100. DataPack (test volumes, sales forecasts, supplier shares) $3,950.
Summary
This comprehensive report contains 409 pages, 35 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the UK coagulation testing market duri...
- Publish Date: February 7, 2017
- $750
Complete report $9,600. DataPack (test volumes, sales forecasts, supplier shares) $6,200.
Summary
This comprehensive report contains 424 pages, 37 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the US coagulation testing market during the...
- Publish Date: February 7, 2017
- $750
This new report from VPGMarketResearch.com provides strategic assessments of major blood banking product suppliers and emerging market entrants. The report presents analyses of major current and emerging suppliers in terms of their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies.
Con...
- Publish Date: February 7, 2017
- $750
